Edition:
United Kingdom

SSY Group Ltd (2005.HK)

2005.HK on Hong Kong Stock

7.85HKD
25 Apr 2018
Change (% chg)

HK$0.01 (+0.13%)
Prev Close
HK$7.84
Open
HK$7.78
Day's High
HK$8.00
Day's Low
HK$7.66
Volume
4,735,652
Avg. Vol
6,698,063
52-wk High
HK$8.50
52-wk Low
HK$2.87

Latest Key Developments (Source: Significant Developments)

SSY Group ‍Obtains China FDA Approvals For Drug Production For Hemofiltration Replacement Fluid
Thursday, 22 Mar 2018 

March 22 (Reuters) - SSY Group Ltd <2005.HK>::‍OBTAINED APPROVALS FOR DRUG PRODUCTION AND REGISTRATION FOR HEMOFILTRATION REPLACEMENT FLUID FROM CHINA FDA.  Full Article

Ssy Group Unit ‍Entered Agreement With Zhengzhou University For Research Of New Liver Fibrosis​ Drug
Monday, 5 Mar 2018 

March 5 (Reuters) - Ssy Group Ltd <2005.HK>::UNIT ‍ENTERED AGREEMENT WITH ZHENGZHOU UNIVERSITY IN RELATION TO RESEARCH AND DEVELOPMENT OF NEW DRUG USED FOR LIVER FIBROSIS​.‍ AGGREGATE INVESTMENT IN RESEARCH AND DEVELOPMENT OF DRUG FOR TREATMENT OF LIVER FIBROSIS​ IS RMB 50 MILLION.  Full Article

SSY Group Updates On Development Of Hemofiltration Basic Solution
Wednesday, 28 Feb 2018 

Feb 28 (Reuters) - SSY Group Ltd <2005.HK>::GETS ‍APPROVAL FOR DRUG PRODUCTION AND REGISTRATION FOR HEMOFILTRATION BASIC SOLUTION (4000ML) FROM CHINA FOOD AND DRUG ADMINISTRATION​.  Full Article

Ssy Group Sees FY ‍Profit Attributable Up In Range Of 30 Pct To 40 Pct
Tuesday, 27 Feb 2018 

Feb 27 (Reuters) - Ssy Group Ltd <2005.HK>::‍PROFIT ATTRIBUTABLE FOR YEAR ENDED 31 DECEMBER 2017 IS EXPECTED TO INCREASE SIGNIFICANTLY RANGING FROM 30% TO 40%​.EXPECTED RESULT DUE TO ‍ INCREASES IN SALES VOLUME AND AVERAGE SELLING PRICE OF INTRAVENOUS INFUSION SOLUTIONS​.  Full Article

SSY Group Updates on Product Development
Monday, 11 Dec 2017 

Dec 11 (Reuters) - SSY Group Ltd <2005.HK>::SSY GROUP-OBTAINED APPROVAL FOR DRUG PRODUCTION & REGISTRATION FOR SODIUM ACETATE RINGER'S INJECTION (500ML) FROM CHINA FOOD & DRUG ADMINISTRATION​.  Full Article

SSY Group says turnover of group for 9 months ended Sept. 30, 2017, HK$2,105 mln, up 24.2 pct
Tuesday, 10 Oct 2017 

Oct 10 (Reuters) - SSY Group Ltd <2005.HK>::‍Gross profit margin of group for nine months ended Sept. 30, 2017 was 55.1​ percent, up 4.4 percent.‍Turnover of group for nine months ended 30 september 2017 is HK$2,105 million, up by 24.2 percent​.  Full Article

SSY Group obtains production approvals from FDA of Hebei province
Wednesday, 30 Aug 2017 

Aug 30 (Reuters) - Ssy Group Ltd <2005.HK>:Obtained production approvals for seven bulk pharmaceuticals as approved from food and drug administration of Hebei province.Production approvals were transferred from a PRC pharmaceutical company at a consideration of RMB35 million.  Full Article

SSY Group posts HY profit attributable of HK$288 mln
Wednesday, 23 Aug 2017 

Aug 23 (Reuters) - SSY Group Ltd <2005.HK>:HY revenue of HK$1,325 million, representing an increase of 19.5 percent.Resolved to pay an interim dividend of hk3 cents per share.HY profit attributable to equity shareholders of company HK$288 million versus HK$210.4 million.  Full Article

SSY Group expects HY profit attributable to increase
Tuesday, 1 Aug 2017 

Aug 1 (Reuters) - SSY Group Ltd <2005.HK>::Profit attributable for hy expected to increase and record an increase of not less than 30 pct.‍Profit attributable to equity holders of company for six months ended 30 June 2017 is expected to increase significantly​.Expected result due to increases in sales volumes and average selling prices of intravenous infusion solutions.  Full Article

SSY Group says 3-mnth gross profit margin was 53.5%
Tuesday, 18 Apr 2017 

April 18 (Reuters) - SSY Group Ltd <2005.HK>::Gross profit margin of group for three months ended 31 March 2017 was 53.5%.Sales of intravenous infusion solution for three months ended 31 March 2017 increased by 25.6%.Turnover of group for three months ended 31 March 2017 increased by 22.6%.  Full Article

BRIEF-SSY Group Announces Master Sale And Purchase Agreement

* ENTERED AGREEMENT WITH A SUBSTANTIAL SHAREHOLDER TO PURCHASE MATERIALS Source text for Eikon: Further company coverage: